Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy

被引：0

作者：

JIAO Xiu-min ^{[1
]}

JIAO Xiu-juan ^{[2
]}

ZHANG Xing-guang ^{[1
]}

XU Xiu-ping ^{[1
]}

WU Jin-xiao ^{[1
]}

YAO Lu ^{[1
]}

ZHAO Jing ^{[1
]}

LU Xiao-feng ^{[1
]}

机构：

[1] Department of Endocrinology,General Hospital of Beijing Military Area

[2] The Third Hospital of Qinhuangdao

来源：

中华医学杂志（英文版） | 2013年 / 126卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R587.2 [糖尿病性昏迷及其他并发症]; R692 [肾疾病];

学科分类号：

1002 ; 100201 ; 100210 ;

摘要：

Diabetic nephropathy(DN)is the most common microvascular complication of diabetes and is one of the major causes of end-stage renal disease(ESRD).Cilostazol,an antiplatelet drug,plays an important role in the prevention and treatment of the chronic complications of diabetes through a series of mechanisms,including anti-inflammation,the inhibition of vascular smooth muscle proliferation,the protection of nerve cells,and the regulation of blood lipids.In this study,we observed the effects of cilostazol on serum soluble cell adhesion molecule-1(sICAM-1)and monocyte

引用

页码：4395 / 4396